ArticleBJC reports2024

A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

Chigusa Morizane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.